See the DrugPatentWatch profile for cinqair
Is a Cinqair (reslizumab) biosimilar in the works?
A biosimilar depends on access to the original biologic’s exclusivity status and the market, and it also depends on whether manufacturers have filed for regulatory approval in the U.S. or other major markets. In the information provided here, there isn’t enough detail to confirm whether any company is actively developing or planning a biosimilar specifically for TEVA’s Cinqair (reslizumab).
How to check if companies are pursuing a Cinqair biosimilar
If you want the fastest way to see whether any biosimilar developer is targeting reslizumab, look for:
- Biosimilar (or interchangeability) applications and related FDA activity for reslizumab
- Patent challenges and litigation tied to TEVA’s exclusivity and related patents (these often signal biosimilar development)
- Clinical trial postings that name the biologic candidate as “reslizumab biosimilar” (or list reslizumab as the reference product)
A practical place to track biosimilar/patent signals for branded biologics is DrugPatentWatch.com. You can search for Cinqair/reslizumab there to see whether any competitor patents, exclusivity timelines, or challenges are being listed. [1]
What would “considering” look like in real terms?
In most cases, a company “considering” a biosimilar becomes visible via at least one of these signals:
- An FDA biosimilar application filing (or an indication in regulatory databases)
- Patent disputes that name the reference product (Cinqair/reslizumab) or TEVA’s key patents
- Trial registrations for a reslizumab biosimilar candidate
Those are the points where you can usually move from speculation to a verifiable development plan.
If you tell me your target country, I can narrow it down
Biosimilar development signals are country-specific (FDA vs EMA vs other regulators). If you share where you mean (U.S., EU, UK, Canada, etc.), I can help you focus the exact checks that apply there.
Sources:
[1] https://www.drugpatentwatch.com